Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and … – Yahoo Finance
By daniellenierenberg
Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and ... Yahoo Finance
AJMC in the Press, February 23, 2024 – AJMC.com Managed Markets Network
By daniellenierenberg
AJMC in the Press, February 23, 2024 AJMC.com Managed Markets Network
Read more:
AJMC in the Press, February 23, 2024 - AJMC.com Managed Markets Network
Expanding the Horizons of Cell and Gene Therapy – RegMedNet
By daniellenierenberg
Expanding the Horizons of Cell and Gene Therapy RegMedNet
Read the original:
Expanding the Horizons of Cell and Gene Therapy - RegMedNet
If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL – SurvivorNet
By daniellenierenberg
If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL SurvivorNet
Continued here:
If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL - SurvivorNet
The strangers who saved each others lives – BBC
By daniellenierenberg
The strangers who saved each others lives BBC
View original post here:
The strangers who saved each others lives - BBC
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries – Corporate Wellness Magazine
By daniellenierenberg
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries Corporate Wellness Magazine
Read more here:
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries - Corporate Wellness Magazine
Statement of Renovaro Inc
By Dr. Matthew Watson
LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:
Go here to see the original:
Statement of Renovaro Inc
Genmab Publishes 2023 Annual Report
By Dr. Matthew Watson
To Read More: Genmab Publishes 2023 Annual ReportHyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
By Dr. Matthew Watson
Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a pivotal Phase 3 clinical trial for Tranexamic Acid Oral Rinse.
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
By Dr. Matthew Watson
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
Read the rest here:
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
By Dr. Matthew Watson
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
See more here:
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
By Dr. Matthew Watson
PARAMUS, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Regional Medical Oncology Center (RMOC) in Wilson, NC as the second site activated in the STAR-LLD Phase 1b clinical trial. The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®). Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
Read more from the original source:
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
By Dr. Matthew Watson
Media Release COPENHAGEN, Denmark; February 14, 2024
More:
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
By Dr. Matthew Watson
SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update.
See the article here:
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell…
By Dr. Matthew Watson
-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery
Go here to read the rest:
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell...
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
By Dr. Matthew Watson
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Visit link:
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
By Dr. Matthew Watson
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2023.
More here:
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024
By Dr. Matthew Watson
TORONTO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
Here is the original post:
Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients…
By Dr. Matthew Watson
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -
See the original post:
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients...
NurExone Launches Licensing Efforts for ExoTherapy Platform
By Dr. Matthew Watson
Huge opportunity for development of nanodrugs for wide variety of clinical indications Huge opportunity for development of nanodrugs for wide variety of clinical indications
Here is the original post:
NurExone Launches Licensing Efforts for ExoTherapy Platform